Haleon PLC EMTN programme publication of base prospectus (1763Z)

TIDMHLN TIDMTTM TIDMTTM

RNS Number : 1763Z

Haleon PLC

12 May 2023

EMTN programme: publication of base prospectus

12 May 2023: Haleon plc (the "Company") (LSE/NYSE: HLN) today announces that the base prospectus regarding Haleon UK Capital plc's and Haleon Netherlands Capital B.V.'s GBP10,000,000,000 Euro Medium Term Note ("EMTN") Programme, guaranteed by the Company, has been published (the "Base Prospectus").

A copy of the Base Prospectus has been submitted to the National Storage Mechanism and will shortly be available for inspection at and can be downloaded from:

https://data.fca.org.uk/#/nsm/nationalstoragemechanism

and

https://www.haleon.com/investors/debt-investors

Ends

 
 Investors                                 Media 
 Sonya Ghobrial       [phone]      Zoe Bird        [phone] 
 Rakesh Patel         [phone]      Nidaa Lone      [phone] 
 Emma White           [phone] 
 Email: [e-mail]      Email: [e-mail] 
 

About Haleon

Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com.

Disclaimer

Please note that the information contained in the Base Prospectus may be addressed to and/or targeted at persons who are residents of particular countries (specified in the Base Prospectus) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the Base Prospectus is not addressed. Prior to relying on the information contained in the Base Prospectus, you must ascertain from the Base Prospectus whether or not you are part of the intended addressees of the information contained in the Base Prospectus.

Your right to access this service is conditional upon complying with the above requirement.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

PDIKFLFFXELBBBL

(END) Dow Jones Newswires

May 12, 2023 04:30 ET (08:30 GMT)